Bierer L, Docherty J P, Young J G, Giller E, Cohen D
Am J Psychiatry. 1984 Feb;141(2):257-60. doi: 10.1176/ajp.141.2.257.
Platelet monoamine oxidase (MAO) activity was significantly lower among 21 chronic schizophrenic patients, 19 of whom were receiving stable doses of antipsychotic medication, than among 16 control subjects. Poor ego functioning and poor outcome were significantly correlated with low MAO activity; current dose of major tranquilizer was negatively but not significantly correlated. The degree of psychopathology, rather than presence or absence of specific symptom constellations, was the significant characteristic of patients with low enzyme levels. This finding is in accordance with those of earlier studies of schizophrenic patients as well as with recent findings in nonschizophrenic samples.
21名慢性精神分裂症患者的血小板单胺氧化酶(MAO)活性显著低于16名对照受试者,其中19名患者正在接受稳定剂量的抗精神病药物治疗。自我功能差和预后不良与低MAO活性显著相关;主要镇静剂的当前剂量呈负相关,但无显著相关性。酶水平低的患者的显著特征是精神病理学程度,而非特定症状群的有无。这一发现与早期对精神分裂症患者的研究结果以及最近在非精神分裂症样本中的发现一致。